However,much of the research has focused on drug therapies to reduce
disease incidence, particularly antidiabetic agents such as alpha-
glucosidase inhibitors, thiazolidinediones and biguanides.
These agents reduced progression to type 2 diabetes by 40–60%
in high-risk adults (Taba´k et al., 2012). However, the cost, access
andtoxicities associatedwithpharmaceuticalmedications limit
their usefulness.